{"organizations": [], "uuid": "959b4f591a7908d5862ab957711db21f304ffb03", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-merck-announces-first-phase-3-stud/brief-merck-announces-first-phase-3-studies-for-pcv-15-its-investigational-pneumococcal-disease-vaccine-idUSFWN1RU0U3", "country": "US", "domain_rank": 408, "title": "BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T15:33:00.000+03:00", "replies_count": 0, "uuid": "959b4f591a7908d5862ab957711db21f304ffb03"}, "author": "", "url": "https://www.reuters.com/article/brief-merck-announces-first-phase-3-stud/brief-merck-announces-first-phase-3-studies-for-pcv-15-its-investigational-pneumococcal-disease-vaccine-idUSFWN1RU0U3", "ord_in_thread": 0, "title": "BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - merck & co inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17, 2018 / 12:33 PM / Updated 9 minutes ago BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine Reuters Staff \nApril 17 (Reuters) - Merck & Co Inc: \n* MERCK ANNOUNCES FIRST PHASE THREE STUDIES FOR PCV-15 (V114) ITS INVESTIGATIONAL PNEUMOCOCCAL DISEASE VACCINE \n* MERCK - FIRST STUDY TO EVALUATE PCV-15 FOLLOWED BY PNEUMOCOCCAL VACCINE POLYVALENT ONE YEAR LATER IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER \n* MERCK - SECOND PHASE 3 STUDY TO EVALUATE PCV-15 FOLLOWED BY PNEUMOCOCCAL VACCINE POLYVALENT GIVEN 8 WEEKS LATER IN ADULTS INFECTED WITH HIV Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-17T15:33:00.000+03:00", "crawled": "2018-04-17T15:52:13.076+03:00", "highlightTitle": ""}